| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
1 company
Luca Benatti is a corporate insider. Luca Benatti's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
The QNCX filings lean toward selling, a net 50,000 shares.
Luca Benatti has 5 Form 4 filings on record from October 2023 to December 2025, all as Quince Therapeutics (QNCX), 2023–2025.
The 5 reported transactions were 3 option or other derivative awards, 1 open-market sale and 1 other transaction.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $174K.
The only open-market sale was 50,000 shares of QNCX at an average $3.47 on December 26, 2025, about $174K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 26, 2025 | QNCX Quince Therapeutics, Inc. | - | Sell | 50,000 | $3.47 | $173,500.00 | -56.1% | -97.4% | - |